BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for lead product candidate, eftilagimod alpha (efti or IMP321), in metastatic breast cancer (MBC).

Iterum Therapeutics plc announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, granting the Company’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson, Professor of the Department of Molec

MCRA, LLC, a leading medical device focused regulatory advisory firm and clinical research organization integrating U.S. and International Regulatory Affairs, Clinical Trial Operations, Reimbursement and Market Access, Healthcare Compliance, Cybersecurity, and Quality Assurance support, is pleased to announce its recent acquisition of Vorpal Technologies K.K.

SIME Diagnostics, a commercial stage company pioneering rapid intensive care diagnostics, today announced the publication of a peer-reviewed study demonstrating that the company’s point-of-care AI platform can identify ARDS patients with low surfactant concentration.

Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, announced that Apnimed will participate in the 32nd Annual Oppenheimer Conference taking place March 15-17, 2022 virtually, and invites investors to view the presentation via webcast and participate in virtual one-on-one meetings.

Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the 32nd Annual Oppenheimer Healthcare Conference.

The Business Intelligence Group today announced that it has awarded Abveris a division of Twist Bioscience, a Best Places to Work 2022.

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.

Selecta Biosciences, Inc. reported financial results for the quarter and full year ended December 31, 2021 and provided a business update.